论文部分内容阅读
目的研究黑素瘤(malignant melanoma,MM)患者癌组织中切除修复交叉互补基因1(ERCC1)mRNA的表达及其与替莫唑胺化疗敏感性的关系。方法应用实时荧光定量PCR技术检测30例晚期MM患者中ERCC1 mRNA的表达情况,分析其与替莫唑胺化疗耐药性的关系。结果检测30例患者中ERCC1 mRNA的高表达率为56.7%(17/30),其表达在不同性别、年龄、组织学类型及临床分期中无明显差异。在ERCC1 mRNA低表达组替莫唑胺化疗有效率为46.2%,而在高表达组化疗有效率为29.4%,2组差异有统计学意义(P<0.05);ERCC1 mRNA高表达组患者的中位生存期为8.4个月,ERCC1 mRNA低表达组的中位生存期为13.6个月,其差异有统计学意义(P<0.05)。结论 ERCC1 mRNA高表达的MM患者较其低表达患者在使用替莫唑胺化疗方案时疗效差,提示ERCC1mRNA高表达的MM患者对替莫唑胺具有耐药性。同时ERCC1 mRNA低表达的患者在使用替莫唑胺化疗时有效率更高,提示我们应用ERCC1 mRNA进行检测时,患者可获得更大的益处。
Objective To investigate the expression of ERCC1 mRNA in cancerous tissues of patients with malignant melanoma (MM) and its relationship with chemosensitivity of temozolomide. Methods The expression of ERCC1 mRNA in 30 patients with advanced MM was detected by real-time fluorescence quantitative PCR. The relationship between the expression of ERCC1 mRNA and the resistance to chemotherapy with temozolomide was analyzed. Results The high expression rate of ERCC1 mRNA in 30 patients was 56.7% (17/30). The expression of ERCC1 mRNA was not significantly different in different gender, age, histological type and clinical stage. The effective rate of chemotherapy with temozolomide was 46.2% in low ERCC1 mRNA expression group and 29.4% in high expression group, the difference was statistically significant (P <0.05). The median survival time of patients with ERCC1 mRNA overexpression For 8.4 months, the median survival time of ERCC1 mRNA low expression group was 13.6 months, with significant difference (P <0.05). Conclusion MM patients with high expression of ERCC1 mRNA have a poorer curative effect than those with low expression of temozolomide, suggesting that patients with MM with ERCC1 mRNA overexpression are resistant to temozolomide. Patients with low expression of ERCC1 mRNA were also more effective in the chemotherapy with temozolomide, suggesting that patients may achieve greater benefit when using ERCC1 mRNA for detection.